The Swiss Federal Government has exercised an option to procure additional seven million booster doses of Moderna’s Covid-19 vaccine, Spikevax, to be supplied in the second half of next year. The latest purchase is apart from the seven million booster doses purchased by the government initially. The prior order will be fulfilled this year. The latest option exercise takes the doses to be supplied to Switzerland to a total of 27.5 million so far. Swissmedic approved the vaccine for active immunisation to prevent Covid-19 in people aged 12 years and above. 

Kintor Pharmaceutical has reported interim assessment data where its nonsteroidal antiandrogen, proxalutamide, failed to meet statistical significance in Phase III clinical trial to treat Covid-19 in the outpatient setting. The data was collected from 348 subjects with mild-to-moderate disease.  With the latest development, the company plans to seek approval from regulatory authorities to modify the trial protocol and enrol infected people at greater risk with several comorbidities and/or unvaccinated. In the interim findings, no safety concerns and treatment-associated serious adverse events were observed.

The Subject Expert Committee (SEC) on COVID-19 of India’s Central Drugs Standard Control Organisation (CDSCO) has advised the grant of emergency use authorisation to Serum Institute of India’s Covid-19 vaccine, Covovax, and Biological E’s vaccine, Corbevax. Furthermore, the committee recommended granting approval to produce and supply Merck’s anti-Covid-19 pill, molnupiravir, for restricted emergency use to treat infected adults. The oral pill is indicated for use in Covid-19 patients with SpO2 levels at 93% and are at greater disease progression risk, including hospital admission or mortality.